原发干燥综合征局部与全身用药疗效与安全性的系统文献综述:为EULAR管理建议提供依据
该系统文献综述评估了原发干燥综合征(SjS)患者局部与全身用药的疗效与安全性,以支持EULAR治疗建议的制定。检索MEDLINE、EMBASE和Cochrane数据库后,证据基于9项随机对照试验(RCT)、18项前瞻性队列研究和5项病例对照研究。局部治疗(如环孢素A滴眼液、毛果芸香碱和西维美林)证据较充分,而全身治疗(如羟氯喹、生物制剂)的RCT证据有限且主要终点多无显著差异。
要点
- 局部治疗口干和眼干的证据较充分,环孢素A滴眼液安全有效。
- 毛果芸香碱和西维美林可改善口腔干燥和唾液流率。
- 羟氯喹400 mg/天及多种生物制剂在RCT中主要终点未优于安慰剂。
核心结论
- 支持原发SjS主要局部治疗选择的证据较扎实,而指导全身治疗的RCT数据有限。
研究设计与样本
- 系统文献综述,检索MEDLINE、EMBASE和Cochrane数据库,纳入病例对照研究、前瞻性队列研究、RCT和系统综述。
- 证据基于9项RCT、18项前瞻性队列研究和5项病例对照研究,对象为符合2002年标准的原发SjS患者。
主要发现
- 两项Cochrane系统文献综述报告局部治疗口干和眼干安全有效。
- 眼部环孢素A在两项RCT(共1039例干眼综合征患者)中安全有效。
- 两项Cochrane系统文献综述关于血清滴眼液和泪道栓的潜在获益在症状和客观指标上均不一致。
- 五项RCT报告毛果芸香碱和西维美林显著改善口腔干燥和唾液流率。
- 一项RCT显示羟氯喹400 mg/天在主要终点(干燥、疲劳和疼痛的VAS复合评分)上与安慰剂无显著差异。
关键数值与推荐
- 原发SjS患者符合2002年标准。
- 眼部环孢素A的RCT共纳入1039例干眼综合征患者。
- 羟氯喹剂量为400 mg/天,主要终点为干燥、疲劳和疼痛的VAS复合评分。
- 英夫利西单抗、阿那白滞素和baminercept的RCT主要终点均未显示优于安慰剂。
- 两项最大RCT随机分配255例患者接受利妥昔单抗或安慰剂,主要终点(VAS复合评分)无显著结果。
临床怎么用
- 原发SjS口干和眼干可优先选择证据支持的局部治疗。
- 全身治疗决策需认识到RCT证据有限,部分药物主要终点未优于安慰剂。
- 利妥昔单抗虽RCT主要终点阴性,但前瞻性研究提示对系统性疾病可能有效。
局限性
- 指导全身治疗的RCT数据有限。
- 部分局部治疗(如血清滴眼液和泪道栓)的获益证据不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate current evidence on the efficacy and safety of topical and systemic medications in patients with primary Sjögren syndrome (SjS) to inform European League Against Rheumatism treatment recommendations. METHODS: The MEDLINE, EMBASE and Cochrane databases were searched for case-control/prospective cohort studies, randomised controlled trials (RCTs) and systematic reviews. RESULTS: Current evidence in primary SjS patients fulfilling the 2002 criteria is based on the data from 9 RCTs, 18 prospective cohort studies and 5 case-control studies. Two Cochrane systematic literature reviews (SLRs) have reported that topical treatments for dry mouth and dry eye are safe and effective. Ocular cyclosporine A was safe and effective in two RCTs including 1039 patients with dry eye syndrome. Two Cochrane SLRs on serum tear drops and plugs showed inconsistency in possible benefits, both for symptoms and objective measures. Five RCTs reported significant improvements in oral dryness and salivary flow rates for pilocarpine and cevimeline. An RCT showed no significant placebo-differences for hydroxychloroquine 400 mg/day for the primary outcome (visual analogue scale (VAS) composite of dryness, fatigue and pain). We identified seven RCTs carried out in primary SjS patients. RCTs using infliximab, anakinra and baminercept found no placebo-differences for the primary outcomes. The two largest RCTs randomised 255 patients to receive rituximab or placebo and reported no significant results in the primary outcome (VAS composite), while prospective studies suggested efficacy in systemic disease. CONCLUSION: The current evidence supporting the use of the main topical therapeutic options of primary SjS is solid, while limited data from RCTs are available to guide systemic therapies.
引用
- Brito-Zerón P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open. 2019. PMID: 31749986. doi:10.1136/rmdopen-2019-001064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。